Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells-Reference-Cited by-同舟云学术

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells

Published:2017-03-07 Issue:17 Volume:8 Page:28971-28989
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Ferreira Renan B.¹,Wang Mengxiong²³,Law Mary E.²³,Davis Bradley J.²³,Bartley Ashton N.¹,Higgins Paul J.⁴,Kilberg Michael S.⁵,Santostefano Katherine E.⁶,Terada Naohiro⁶,Heldermon Coy D.⁷,Castellano Ronald K.¹,Law Brian K.²³

Affiliation:

1. Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

2. Department of Pharmacology & Therapeutics, University of Florida, Gainesville, FL 32610, USA

3. UF-Health Cancer Center, University of Florida, Gainesville, FL 32610, USA

4. Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY 12208, USA

5. Department of Biochemistry, University of Florida, Gainesville, FL, 32610, USA

6. Department of Pathology, Immunology, and Laboratory Medicine, Center for Cellular Reprogramming, University of Florida College of Medicine, Gainesville, FL 32610, USA

7. Department of Medicine, University of Florida, Gainesville, FL, 32610, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DR5 disulfide bonding as a sensor and effector of protein folding stress;2024-03-07

2. Anticancer Agents Derived from Cyclic Thiosulfonates: Structure‐Reactivity and Structure‐Activity Relationships;ChemMedChem;2022-05-23

3. Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death;Cancer Letters;2022-05

4. Repurposing Tranexamic Acid as an Anticancer Agent;Frontiers in Pharmacology;2022-01-13

5. Proteotoxicity and endoplasmic reticulum stress-mediated cell death;Mechanisms of Cell Death and Opportunities for Therapeutic Development;2022